Oral drug combo tested for rare blood cancer
NCT ID NCT03506373
Summary
This study tested a combination of two oral drugs, ibrutinib and ixazomib, for patients with Waldenström macroglobulinemia, a rare type of blood cancer. The goal was to see if taking these two drugs together was safe and effective for patients whose cancer was newly diagnosed, had returned, or was not responding to other treatments. The trial was stopped early and enrolled 21 patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.